G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome

Haematologica

Volumn 89, Issue 9, 2004, Pages 1134-1138

  Burzotta, Francesco ^a,d   Leone, Antonio Maria ^a   Paciaroni, Katia ^b   De Stefano, Valerio ^b   Rossi, Elena ^b   Testa, Luca ^a   Giannico, Floriana ^a   Leone, Giuseppe ^b   Maseri, Attilio ^a,c   Crea, Filippo ^a   Andreotti, Felicita ^a  

^a Institute of Cardiology   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d NONE   (Italy)

Author keywords

Acute coronary syndromes; Cardiovascular risk factors; Gene polymorphism; Myocardial revascularization; Outcome; Prothrombin

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; DNA POLYMORPHISM; FEMALE; GENE; GENE LOCUS; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POPULATION RESEARCH; PROSPECTIVE STUDY; PROTHROMBIN GENE; RISK ASSESSMENT; STATISTICAL ANALYSIS; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS;

3' UNTRANSLATED REGIONS; ADULT; ANGINA, UNSTABLE; COHORT STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HETEROZYGOTE; HUMANS; LIFE TABLES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; PROSPECTIVE STUDIES; PROTHROMBIN; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOPHILIA; TREATMENT OUTCOME;

EID: 4644297607     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
2. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. A systematic review. Circulation 2001;104:3063-8.
3. Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: a meta-analysis of published studies. Am Heart J 2003;146:948-57.
4. Burzotta F, Paciaroni K, De Stefano V, Crea F, Maseri A, Leone G, et al. The G20210A prothrombin gene polymorphism and coronary ischemic syndromes: a phenotype-specific meta-analysis of 12,034 subjects. Heart 2004;90:82-6.
5. Butt C, Zheng H, Randell E, Robb D, Parfrey P, Xie YG. Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood 2003;101:3037-41.
6. Burzotta F, Paciaroni K, Andreotti F, Casorelli I, De Stefano V. G20210A prothrombin gene polymorphism and extent of coronary disease. Thromb Haemost 2000;84:142-3.
7. Burzotta F, Paciaroni K, De Stefano V, Chiusolo P, Manzoli A, Casorelli I, et al. Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J 2002;23:26-30.
8. Van de Water NS, French JK, Lund M, Hyde TA, White HD, Browett PJ. Prevalence of factors V Leiden and prothrombin variant G20210A in patients aged <45 years with no significant stenoses at angiography three to four weeks after myocardial infarction. J Am Coll Cardiol 2000;36:717-722.
9. Bothig S. WHO MONICA project: objectives and design. Int J Epidemiol 1989;18:S29-37.
10. Braunwald E. Unstable angina: a classification. Circulation 1989;80:410-4.
11. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during InStability in Coronary artery disease. Lancet 2000;356:9-16.
12. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy). Thrombolysis in Myocardial Infarction 18 Investigators. N Engl J Med 2001;344:1879-87.
13. Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, et al. Three-year outcome after coronary stenting versus bypass surgery for the treatment of multi-vessel disease. Arterial Revascularization Therapy Study (ARTS) Investigators. Circulation 2004;109:1114-20.
14. Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430-3.